

Laurent Greillier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5175791/publications.pdf>

Version: 2024-02-01

69
papers

4,262
citations

218592

26
h-index

118793

62
g-index

70
all docs

70
docs citations

70
times ranked

4703
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1405-1414. | 6.3 | 753 |
| 2 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386. | 6.3 | 638 |
| 3 | Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 239-253. | 5.1 | 342 |
| 4 | Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966. | 3.2 | 206 |
| 5 | Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119. | 0.5 | 189 |
| 6 | Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1095-1101. | 0.5 | 159 |
| 7 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953. | 3.1 | 151 |
| 8 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359. | 0.8 | 147 |
| 9 | Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-“small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 201-207. | 1.1 | 137 |
| 10 | A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 903-913. | 0.5 | 132 |
| 11 | Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3600. | 0.8 | 121 |
| 12 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558. | 0.5 | 108 |
| 13 | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499. | 0.6 | 99 |
| 14 | The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646. | 1.3 | 98 |
| 15 | Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1224-1233. | 5.1 | 80 |
| 16 | Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46. | 1.3 | 69 |
| 17 | Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. <i>Cancer</i> , 2007, 110, 2248-2252. | 2.0 | 65 |
| 18 | Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1762-1770. | 0.5 | 60 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2020, 58, 1-24. | 0.6 | 50 |
| 20 | Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575. | 1.1 | 49 |
| 21 | Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Therapeutic Advances in Medical Oncology, 2016, 8, 198-208. | 1.4 | 46 |
| 22 | A Phase 1&2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of Thoracic Oncology, 2021, 16, 1559-1569. | 0.5 | 41 |
| 23 | Personalised medicine for nonsmall cell lung cancer. European Respiratory Review, 2017, 26, 170066. | 3.0 | 37 |
| 24 | Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology, 2022, 40, 719-728. | 0.8 | 37 |
| 25 | EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. European Journal of Cancer, 2019, 122, 109-114. | 1.3 | 33 |
| 26 | Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer, 2019, 127, 96-102. | 0.9 | 31 |
| 27 | Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512. | 2.9 | 25 |
| 28 | Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget, 2018, 9, 8253-8262. | 0.8 | 25 |
| 29 | Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. Journal of Clinical Medicine, 2020, 9, 3861. | 1.0 | 23 |
| 30 | Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. European Respiratory Review, 2018, 27, 170098. | 3.0 | 21 |
| 31 | PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer, 2022, 23, e243-e246. | 1.1 | 20 |
| 32 | MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. British Journal of Cancer, 2019, 120, 387-397. | 2.9 | 19 |
| 33 | Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. Cancers, 2021, 13, 6210. | 1.7 | 19 |
| 34 | Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S1032-S1036. | 0.6 | 16 |
| 35 | Necitumumab for non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1231-1239. | 1.4 | 14 |
| 36 | Current and Former Smokers: Who Wants To Be Screened?. Clinical Lung Cancer, 2018, 19, 493-501. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5759-5765. | 3.2 | 13 |
| 38 | Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. <i>European Journal of Cancer</i> , 2014, 50, 2771-2782. | 1.3 | 11 |
| 39 | LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study. <i>Annals of Oncology</i> , 2020, 31, S1183. | 0.6 | 11 |
| 40 | Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. <i>Respiratory Medicine and Research</i> , 2020, 78, 100769. | 0.4 | 11 |
| 41 | Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. <i>Lung Cancer</i> , 2021, 158, 146-150. | 0.9 | 11 |
| 42 | First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial. <i>European Respiratory Journal</i> , 2020, 56, 1902066. | 3.1 | 10 |
| 43 | Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). <i>Cancers</i> , 2022, 14, 769. | 1.7 | 9 |
| 44 | Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?. <i>World Neurosurgery</i> , 2017, 107, 1047.e1-1047.e4. | 0.7 | 8 |
| 45 | Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107. | 1.8 | 8 |
| 46 | Octogenarians treated for thoracic and lung cancers: Impact of comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2021, 12, 402-409. | 0.5 | 8 |
| 47 | Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S323-S326. | 1.3 | 6 |
| 48 | Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 11-17. | 1.1 | 6 |
| 49 | Development and Validation of a Simplified Prognostic Score in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100016. | 0.6 | 6 |
| 50 | Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?. <i>Lung Cancer</i> , 2021, 152, 86-93. | 0.9 | 6 |
| 51 | First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression $\geq 50\%$. <i>Future Oncology</i> , 2021, 17, 3007-3016. | 1.1 | 6 |
| 52 | Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. <i>European Journal of Cancer</i> , 2022, 162, 118-127. | 1.3 | 6 |
| 53 | High Serum Vitamin B12 Levels Associated with C-reactive Protein in Older Patients with Cancer. <i>Oncologist</i> , 2020, 25, e1980-e1989. | 1.9 | 5 |
| 54 | Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival. <i>Clinical Lung Cancer</i> , 2021, 22, e405-e414. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer, 2021, 157, 124-130. | 0.9 | 5 |
| 56 | Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918. | 0.9 | 5 |
| 57 | Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer. Journal of Geriatric Oncology, 2022, 13, 850-855. | 0.5 | 5 |
| 58 | Adrenal surgery for oligometastatic tumors improves survival in selected cases. Journal of Visceral Surgery, 2017, 154, 87-91. | 0.4 | 4 |
| 59 | Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. Preventive Medicine Reports, 2018, 10, 332-336. | 0.8 | 4 |
| 60 | Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, S383-S386. | 1.3 | 4 |
| 61 | Functional status in older patients with cancer. Journal of Geriatric Oncology, 2021, , . | 0.5 | 4 |
| 62 | Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients. Cancers, 2022, 14, 169. | 1.7 | 4 |
| 63 | First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. Translational Cancer Research, 2019, 8, 2514-2516. | 0.4 | 3 |
| 64 | Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02â€15 study). Lung Cancer, 2021, 161, 122-127. | 0.9 | 2 |
| 65 | Functional status in older patients with lung cancer: an observational cohort study. Supportive Care in Cancer, 2022, 30, 3817-3827. | 1.0 | 2 |
| 66 | The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 987-996. | 0.4 | 1 |
| 67 | La surr  nalectomie am  liore la survie de patients s  lectionn  s porteurs d  un cancer oligom  tastatique. Journal De Chirurgie Visc  rale, 2017, 154, 94-98. | 0.0 | 0 |
| 68 | Prise en charge diagnostique et th  rapeutique du m  soth  liome pleural malin en 2020. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S141-2S149. | 0.0 | 0 |
| 69 | Successful Lung Cryoablation for a Bulky Lung Carcinoma. Journal of Vascular and Interventional Radiology, 2021, 32, 610. | 0.2 | 0 |